Soligenix, Inc.
(NASDAQ : SNGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.29%300.261.4%$596.56m
AMGNAmgen, Inc.
0.15%233.771.3%$511.86m
GILDGilead Sciences, Inc.
1.74%67.081.0%$364.16m
REGNRegeneron Pharmaceuticals, Inc.
1.06%372.262.6%$296.10m
VRTXVertex Pharmaceuticals, Inc.
0.08%223.251.9%$267.50m
ILMNIllumina, Inc.
2.08%326.473.5%$239.80m
ALXNAlexion Pharmaceuticals, Inc.
6.02%113.892.0%$195.68m
ARWRArrowhead Pharmaceuticals, Inc.
2.66%67.2712.0%$195.66m
EXASEXACT Sciences Corp.
3.15%86.2424.0%$182.79m
CLVSClovis Oncology, Inc.
8.47%9.6114.7%$181.81m
SRPTSarepta Therapeutics, Inc.
-0.46%109.4614.6%$145.45m
AAgilent Technologies, Inc.
0.88%82.251.6%$143.48m
NBIXNeurocrine Biosciences, Inc.
0.28%116.815.0%$128.05m
BMRNBioMarin Pharmaceutical, Inc.
-0.20%79.924.3%$126.79m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$126.10m

Company Profile

Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.